EXHIBIT 99.1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: February 14, 2025

 

 

LYNX1 CAPITAL MANAGEMENT LP

By: Lynx1 Capital Management GP LLC, General Partner

   
  By: /s/ Weston Nichols
  Name:  Weston Nichols   
  Title:    Sole Member
   
   
  /s/ Weston Nichols
  WESTON NICHOLS

 

Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Allogene Therapeutics Charts.
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Allogene Therapeutics Charts.